The Lynx Group
Cholangiocarcinoma News

Current Approaches to Treatment of Advanced CCA

Videos — January 10, 2020

Featuring:

Milind M. Javle, MD
Professor
Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas
M.D. Anderson Cancer Center
Houston, TX
Chair
NCI Task Force: Hepatobiliary Cancers
Angela Lamarca, MD, PhD, MSc
The Christie NHS Foundation Trust
Manchester, UK

Dr Angela Lamarca discusses approaches to first- and second-line therapy for patients with advanced CCA. She touches on current standards of care with combination chemotherapy, and the fact that a change from first-line to second-line therapy is usually done when there is evidence of radiographic progression of disease on first-line therapy. Dr Lamarca looks to the future when the use of molecular profiling may open the door to targeted therapies.

Related Items

Evolution in Biomarker Testing in CCA
By Jesús Bañales, PhD; Antoine Hollebecque, MD; Milind M. Javle, MD; Angela Lamarca, MD, PhD, MSc
Videos
Using next-generation sequencing to detect FGFR fusion partners and co-mutations to improve efficacy in treating CCA
Incorporating FGFR Inhibitors into the Treatment Paradigm for Cholangiocarcinoma: Current Concepts and Future Directions
By Mitesh J. Borad, MD; Milind M. Javle, MD; Michael Morse, MD, FACP, MHS; Lewis R. Roberts, MB, ChB, PhD
June/July 2021, Vol 2, No 2
On January 15, 2021, experts in the management of patients with cholangiocarcinoma (CCA) convened for a virtual accredited continuing education satellite symposium held during the 2021 annual meeting of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. The goal was to educate healthcare providers on various aspects of CCA, including epidemiology, current standards of care, unmet clinical needs, the safety and efficacy of fibroblast growth factor receptor (FGFR) inhibitors as second-line therapy, and practical approaches to incorporating FGFR inhibitors into the treatment paradigm for the disease.
Considering Toxicities Associated with Specific and Pan-FGFR Inhibitors
By Jesús Bañales, PhD; Antoine Hollebecque, MD; Milind M. Javle, MD; Angela Lamarca, MD, PhD, MSc
Videos
Drs Javle, Báñales, and Hollebecque describe their thoughts about the use of pan-FGFR inhibitors compared with those that primarily target FGFR2 and the potential of treating CCA with inhibitors of FGFR1, 3, and 4. Moreover, they consider the most common adverse events associated with inhibitors of FGFR2, of which the most difficult to manage are hyperphosphatemia, nail toxicity, eye toxicity, and fatigue. The importance of educating oncologists on how to treat these toxicities is key to maintaining dose intensity of FGFR inhibitors.
Continuing Progress in Cholangiocarcinoma and Bilary Tract Cancers
By Milind M. Javle, MD
March 2021, Vol 2, No 1
Dear Colleagues, It gives me great pleasure to introduce the March issue of CCA News. Once again, we have several recent developments in cholangiocarcinoma (CCA) clinical research, and these have been reviewed by leaders in the field.
The Role of FGFR Inhibitors in Treating FGFR2 Fusion–Positive Cholangiocarcinoma
By Antoine Hollebecque, MD; Milind M. Javle, MD
Videos
Drs Javle and Hollebecque review the phase 2 clinical trial efficacy data of pemigatinib, infigratinib, and futibatinib as second-line therapy of FGFR2 fusion–positive cholangiocarcinoma, and explore use of these agents in the first-line and adjuvant settings.

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to receive the free CCA News print publication or weekly e‑Newsletter.

I'd like to receive: